Haemonetics Corporation (HAE) reported $1.38B of revenue for the twelve months ended Sep 26, 2026. That is up 4.1% from the year before. Revenue for fiscal 2026 was $1.33B.

Yes. Haemonetics Corporation earned $103.91M in net income for the twelve months ended Sep 26, 2026, a net margin of 7.5%.

How much cash and debt does HAE have?

Haemonetics Corporation reported $260.71M in cash and cash equivalents and $1.12B of debt on its most recent balance sheet in SEC filings.

How fast is HAE revenue growing?

Haemonetics Corporation's revenue changed -2.0% in fiscal 2026, to $1.33B. Its compound annual growth rate was +8.9% over 5 years.

What is HAE gross margin?

Haemonetics Corporation's gross profit was $824.31M on $1.38B of revenue for the twelve months ended Sep 26, 2026, a gross margin of 59.6%.

What is HAE free cash flow?

Haemonetics Corporation generated $298.24M of free cash flow for the twelve months ended Sep 26, 2026, which is operating cash flow of $344.93M less capital expenditures.

What is HAE earnings per share?

Diluted earnings per share were $2.26 for the twelve months ended Sep 26, 2026, from SEC filings, restated for any stock split those filings show.

When did HAE last report financial results?

The latest statements here come from Haemonetics Corporation's 10-Q filed on Nov 5, 2026, covering the period ended Sep 26, 2026.

Financials · HAE

Haemonetics Corporation (HAE) financials

For the twelve months ended Sep 26, 2026, Haemonetics Corporation reported $1.38B of revenue and $103.91M of net income.

Revenue, TTM: $1.38B
Revenue growth, YoY: +4.1%
Net income, TTM: $103.91M
Net income growth, YoY: -38.2%
Net margin: 7.5%
Free cash flow, TTM: $298.24M
EPS, diluted, TTM: $2.26
EPS growth, YoY: -33.9%
Cash: $260.71M
Total debt: $1.12B
P/E: 51.80
P/S: 3.89
Market cap: $5.38B

Annual revenue$1.33B

FY2017FY2026

Annual net income$97.31M

FY2017FY2026

Annual free cash flow$260.44M

FY2017FY2026

HAE revenue and earnings growth

HAE revenueQ2 2027$357.76M

Quarter YoY: +9.3%
QoQ: +5.4%
FY YoY: -2.0%
5Y CAGR: +8.9%

HAE revenue was $357.76M in fiscal Q2 2027 (ended Sep 26, 2026), up 9.3% from a year earlier and up 5.4% from the prior quarter. For the full fiscal 2026 it was $1.33B, down 2.0% from fiscal 2025. Compound annual growth was +8.9% over 5 years. It rose in 7 of the last 9 fiscal years.

HAE net incomeQ2 2027$46.30M

Quarter YoY: +19.7%
QoQ: +40.3%
FY YoY: -42.0%
5Y CAGR: +4.1%

HAE net income was $46.30M in fiscal Q2 2027 (ended Sep 26, 2026), up 19.7% from a year earlier and up 40.3% from the prior quarter. For the full fiscal 2026 it was $97.31M, down 42.0% from fiscal 2025. Compound annual growth was +4.1% over 5 years. It rose in 6 of the last 8 fiscal years.

HAE EPSQ2 2027$1.00

Quarter YoY: +23.5%
QoQ: +38.9%
FY YoY: -38.1%
5Y CAGR: +5.8%

HAE diluted EPS was $1.00 in fiscal Q2 2027 (ended Sep 26, 2026), up 23.5% from a year earlier and up 38.9% from the prior quarter. For the full fiscal 2026 it was $2.05, down 38.1% from fiscal 2025. Compound annual growth was +5.8% over 5 years.

HAE free cash flowQ2 2027$113.33M

Quarter YoY: +6.6%
QoQ: +155.1%
FY YoY: +82.8%
5Y CAGR: +29.4%
10Y CAGR: +29.6%

HAE free cash flow was $113.33M in fiscal Q2 2027 (ended Sep 26, 2026), up 6.6% from a year earlier and up 155.1% from the prior quarter. For the full fiscal 2026 it was $260.44M, up 82.8% from fiscal 2025. Compound annual growth was +29.4% over 5 years and +29.6% over 10 years. It rose in 7 of the last 10 fiscal years. Fiscal 2026 is the highest of the 15 fiscal years on file.

Export CSV

Income statement

Income statement
Line item	FY2026 Mar 28, 2026	FY2025 Mar 29, 2025	FY2024 Mar 30, 2024	FY2023 Apr 1, 2023	FY2022 Apr 2, 2022	FY2021 Apr 3, 2021	FY2020 Mar 28, 2020	FY2019 Mar 30, 2019	FY2018 Mar 31, 2018	FY2017 Apr 1, 2017
Revenue	$1.33B	$1.36B	$1.31B	$1.17B	$993.20M	$870.46M	$988.48M	$967.58M	$903.92M	$886.12M
Cost of revenue	$546.44M	$611.87M	$617.51M	$553.56M	$487.69M	$472.63M	$503.97M	$550.04M	$492.01M	$507.62M
Gross profit	$787.59M	$748.96M	$691.55M	$615.10M	$505.50M	$397.84M	$484.51M	$417.54M	$411.91M	$378.49M
Research and development	$59.77M	$62.72M	$54.44M	$50.13M	$46.80M	$32.86M	$30.88M	$35.71M	$39.23M	$37.56M
Selling, general and admin	$442.42M	$436.79M	$429.78M	$376.68M	$340.14M	$275.22M	$282.02M	$273.47M	$316.52M	$301.73M
Operating income	$156.73M	$221.82M	$164.88M	$156.03M	$80.75M	$89.75M	$103.35M	$83.55M	$56.16M	-$19.38M
Pre-tax income	$128.03M	$212.07M	$151.87M	$141.40M	$63.63M	$72.91M	$87.15M	$73.63M	$59.63M	-$27.48M
Income tax	$30.72M	$44.39M	$34.31M	$26.00M	$20.25M	-$6.56M	$10.63M	$18.61M	$14.06M	-$1.21M
Net income	$97.31M	$167.68M	$117.56M	$115.40M	$43.38M	$79.47M	$76.53M	$55.02M	$45.57M	-$26.27M
EPS, basic	$2.06	$3.33	$2.32	$2.27	$0.85	$1.57	$1.51	$1.07	$0.86	-$0.51
EPS, diluted	$2.05	$3.31	$2.29	$2.24	$0.84	$1.55	$1.48	$1.04	$0.85	-$0.51
Diluted shares	47.4M	50.7M	51.4M	51.4M	51.4M	51.3M	51.8M	52.9M	53.5M	51.5M

Balance sheet

Balance sheet
Line item	FY2026 Mar 28, 2026	FY2025 Mar 29, 2025	FY2024 Mar 30, 2024	FY2023 Apr 1, 2023	FY2022 Apr 2, 2022	FY2021 Apr 3, 2021	FY2020 Mar 28, 2020	FY2019 Mar 30, 2019	FY2018 Mar 31, 2018	FY2017 Apr 1, 2017
Cash and equivalents	$245.44M	$306.76M	$178.80M	$284.47M	$259.50M	$192.31M	$137.31M	$169.35M	$180.17M	$139.56M
Receivables	$216.85M	$202.66M	$206.56M	$179.14M	$159.38M	$127.56M	$165.21M	$185.03M	$151.23M	$152.68M
Inventory	$306.37M	$365.14M	$317.20M	$259.38M	$293.03M	$322.61M	$270.28M	$194.34M	$160.80M	$176.93M
Current assets	$834.88M	$934.98M	$768.90M	$769.72M	$756.03M	$693.55M	$603.64M	$576.12M	$521.18M	$510.03M
Goodwill	$656.37M	$604.27M	$565.08M	$466.23M	$467.29M	$466.44M	$210.65M	$210.82M	$211.40M	$210.84M
Total assets	$2.40B	$2.45B	$2.20B	$1.93B	$1.86B	$1.82B	$1.27B	$1.27B	$1.24B	$1.24B
Current liabilities	$282.60M	$578.11M	$300.38M	$251.82M	$442.27M	$253.50M	$274.82M	$235.76M	$384.70M	$211.18M
Short-term debt	$5.01M	$303.56M	$10.23M	$11.78M	$214.15M	$17.02M	$76.98M	$27.67M	$194.26M	$61.02M
Long-term debt	$1.22B	$921.23M	$797.56M	$754.10M	$559.44M	$690.59M	$305.51M	$322.45M	$59.42M	$253.63M
Total debt	$1.22B	$1.22B	$807.79M	$765.89M	$773.59M	$707.61M	$382.49M	$350.12M	$253.68M	$314.65M
Shareholders' equity	$796.32M	$820.84M	$959.96M	$818.00M	$749.42M	$731.67M	$587.11M	$667.87M	$752.43M	$739.61M

Cash flow

Cash flow
Line item	FY2026 Mar 28, 2026	FY2025 Mar 29, 2025	FY2024 Mar 30, 2024	FY2023 Apr 1, 2023	FY2022 Apr 2, 2022	FY2021 Apr 3, 2021	FY2020 Mar 28, 2020	FY2019 Mar 30, 2019	FY2018 Mar 31, 2018	FY2017 Apr 1, 2017
Operating cash flow	$293.22M	$181.72M	$181.75M	$273.06M	$172.26M	$108.81M	$158.22M	$159.28M	$220.35M	$159.74M
Capital expenditures	$32.78M	$39.28M	$38.13M	$191.33M	$96.51M	$37.04M	$48.76M	$118.96M	$74.80M	$76.14M
Free cash flow	$260.44M	$142.45M	$143.63M	$81.73M	$75.75M	$71.77M	$109.46M	$40.32M	$145.55M	$83.60M
Investing cash flow	-$179.55M	-$161.90M	-$322.39M	-$143.79M	-$86.34M	-$425.44M	-$57.18M	-$116.15M	-$63.04M	-$73.31M
Financing cash flow	-$178.46M	$108.82M	$38.16M	-$100.36M	-$15.75M	$367.45M	-$131.21M	-$50.63M	-$120.64M	-$60.41M
Share repurchases	$175.00M	$225.00M	$0	$75.00M	$0	$0	$175.00M	$160.00M	$100.00M	$0
Stock-based compensation	$33.83M	$29.64M	$28.33M	$25.58M	$24.36M	$25.52M	$20.45M	$17.19M	$13.03M	$9.15M
Depreciation and amortization	$111.72M	$115.59M	$97.22M	$93.31M	$97.75M	$84.29M	$110.29M	$109.42M	$89.25M	$89.73M

Key ratios

Key ratios
Line item	FY2026 Mar 28, 2026	FY2025 Mar 29, 2025	FY2024 Mar 30, 2024	FY2023 Apr 1, 2023	FY2022 Apr 2, 2022	FY2021 Apr 3, 2021	FY2020 Mar 28, 2020	FY2019 Mar 30, 2019	FY2018 Mar 31, 2018	FY2017 Apr 1, 2017
Revenue growth, YoY	-2.0%	4.0%	12.0%	17.7%	14.1%	-11.9%	2.2%	7.0%	2.0%	-
Net income growth, YoY	-42.0%	42.6%	1.9%	166.1%	-45.4%	3.8%	39.1%	20.7%	-	-
EPS growth, YoY	-38.1%	44.5%	2.2%	166.7%	-45.8%	4.7%	42.3%	22.4%	-	-
Gross margin	59.0%	55.0%	52.8%	52.6%	50.9%	45.7%	49.0%	43.2%	45.6%	42.7%
Operating margin	11.7%	16.3%	12.6%	13.4%	8.1%	10.3%	10.5%	8.6%	6.2%	-2.2%
Net margin	7.3%	12.3%	9.0%	9.9%	4.4%	9.1%	7.7%	5.7%	5.0%	-3.0%
Free cash flow margin	19.5%	10.5%	11.0%	7.0%	7.6%	8.2%	11.1%	4.2%	16.1%	9.4%
Return on equity	12.2%	20.4%	12.2%	14.1%	5.8%	10.9%	13.0%	8.2%	6.1%	-3.6%
Return on assets	4.1%	6.8%	5.4%	6.0%	2.3%	4.4%	6.0%	4.3%	3.7%	-2.1%
Current ratio	2.95	1.62	2.56	3.06	1.71	2.74	2.20	2.44	1.35	2.42
Debt to equity	1.54	1.49	0.84	0.94	1.03	0.97	0.65	0.52	0.34	0.43

Income statement

Income statement
Line item	Q2 2027 Sep 26, 2026	Q1 2027 Jun 27, 2026	Q4 2026* Mar 28, 2026	Q3 2026 Dec 27, 2025	Q2 2026 Sep 27, 2025	Q1 2026 Jun 28, 2025	Q4 2025* Mar 29, 2025	Q3 2025 Dec 28, 2024	Q2 2025 Sep 28, 2024	Q1 2025 Jun 29, 2024	Q4 2024* Mar 30, 2024	Q3 2024 Dec 30, 2023
Revenue	$357.76M	$339.38M	$346.35M	$338.97M	$327.31M	$321.39M	$330.60M	$348.54M	$345.51M	$336.17M	$343.29M	$336.25M
Cost of revenue	$136.85M	$136.58M	$148.14M	$136.58M	$132.57M	$129.15M	$137.55M	$155.00M	$158.07M	$161.25M	$167.38M	$158.38M
Gross profit	$220.91M	$202.80M	$198.21M	$202.39M	$194.74M	$192.24M	$193.05M	$193.55M	$187.44M	$174.92M	$175.91M	$177.87M
Research and development	$17.03M	$16.20M	$14.45M	$14.19M	$14.87M	$16.26M	$18.30M	$15.83M	$14.14M	$14.45M	$15.86M	$13.27M
Selling, general and admin	$118.36M	$118.94M	$120.93M	$109.15M	$101.61M	$110.72M	$115.14M	$106.46M	$106.95M	$108.25M	$109.26M	$111.71M
Operating income	$75.12M	$57.46M	-$23.02M	$67.40M	$58.49M	$53.87M	$71.33M	$59.03M	$51.70M	$39.76M	$29.94M	$45.98M
Pre-tax income	$62.86M	$47.57M	-$28.40M	$59.98M	$51.28M	$45.17M	$70.74M	$49.92M	$44.70M	$46.71M	$23.41M	$44.03M
Income tax	$16.55M	$14.56M	-$8.25M	$15.23M	$12.60M	$11.14M	$12.76M	$12.42M	$10.87M	$8.34M	$3.05M	$12.79M
Net income	$46.30M	$33.01M	-$20.15M	$44.74M	$38.68M	$34.03M	$57.98M	$37.49M	$33.83M	$38.37M	$20.37M	$31.24M
EPS, basic	$1.02	$0.73	-$0.42	$0.96	$0.81	$0.71	$1.17	$0.75	$0.66	$0.75	$0.40	$0.62
EPS, diluted	$1.00	$0.72	-$0.41	$0.95	$0.81	$0.70	$1.17	$0.74	$0.66	$0.74	$0.40	$0.61
Diluted shares	46.5M	45.7M	-	47.0M	47.7M	48.4M	-	50.6M	51.2M	51.6M	-	51.4M

Balance sheet

Balance sheet
Line item	Q2 2027 Sep 26, 2026	Q1 2027 Jun 27, 2026	Q4 2026* Mar 28, 2026	Q3 2026 Dec 27, 2025	Q2 2026 Sep 27, 2025	Q1 2026 Jun 28, 2025	Q4 2025* Mar 29, 2025	Q3 2025 Dec 28, 2024	Q2 2025 Sep 28, 2024	Q1 2025 Jun 29, 2024	Q4 2024* Mar 30, 2024	Q3 2024 Dec 30, 2023
Cash and equivalents	$260.71M	$223.38M	$245.44M	$363.37M	$296.43M	$292.90M	$306.76M	$320.85M	$299.28M	$344.43M	$178.80M	$193.98M
Receivables	$224.95M	$216.07M	$216.85M	$195.71M	$207.07M	$200.75M	$202.66M	$211.95M	$213.53M	$201.49M	$206.56M	$211.61M
Inventory	$305.01M	$306.74M	$306.37M	$321.19M	$336.21M	$360.53M	$365.14M	$359.61M	$382.11M	$373.79M	$317.20M	$304.02M
Current assets	$855.53M	$810.83M	$834.88M	$943.67M	$899.68M	$913.16M	$934.98M	$1.01B	$955.90M	$978.58M	$768.90M	$764.98M
Goodwill	$657.10M	$656.88M	$656.37M	$606.83M	$606.10M	$607.30M	$604.27M	$605.27M	$616.16M	$613.35M	$565.08M	$555.00M
Total assets	$2.41B	$2.37B	$2.40B	$2.49B	$2.44B	$2.46B	$2.45B	$2.53B	$2.53B	$2.54B	$2.20B	$2.20B
Current liabilities	$300.84M	$263.24M	$282.60M	$539.87M	$548.32M	$531.41M	$578.11M	$253.23M	$273.95M	$260.08M	$300.38M	$261.75M
Short-term debt	$9.64M	$4.96M	$5.01M	$304.75M	$304.33M	$303.95M	$303.56M	$5.08M	$5.43M	$5.11M	$10.23M	$13.74M
Long-term debt	$1.11B	$1.17B	$1.22B	$919.99M	$920.39M	$920.83M	$921.23M	$1.22B	$1.22B	$1.22B	$797.56M	$856.85M
Total debt	$1.12B	$1.17B	$1.22B	$1.22B	$1.22B	$1.22B	$1.22B	$1.22B	$1.22B	$1.22B	$807.79M	$870.59M
Shareholders' equity	$898.50M	$837.10M	$796.32M	$911.45M	$849.17M	$882.30M	$820.84M	$906.86M	$878.85M	$905.37M	$959.96M	$943.32M

Cash flow

Cash flow
Line item	Q2 2027 Sep 26, 2026	Q1 2027 Jun 27, 2026	Q4 2026* Mar 28, 2026	Q3 2026 Dec 27, 2025	Q2 2026 Sep 27, 2025	Q1 2026 Jun 28, 2025	Q4 2025* Mar 29, 2025	Q3 2025 Dec 28, 2024	Q2 2025 Sep 28, 2024	Q1 2025 Jun 29, 2024	Q4 2024* Mar 30, 2024	Q3 2024 Dec 30, 2023
Operating cash flow	$128.10M	$52.32M	$70.94M	$93.56M	$111.32M	$17.39M	$116.56M	$43.77M	$48.82M	-$27.42M	$64.08M	-$540.0K
Capital expenditures	$14.77M	$7.91M	$17.66M	$6.35M	$5.02M	$3.75M	$15.64M	$8.55M	$9.43M	$5.66M	$6.68M	$14.65M
Free cash flow	$113.33M	$44.42M	$53.28M	$87.22M	$106.31M	$13.64M	$100.91M	$35.22M	$39.39M	-$33.08M	$57.40M	-$15.19M
Investing cash flow	-$24.29M	-$22.23M	-$86.61M	-$29.47M	-$30.47M	-$33.00M	$18.04M	-$17.37M	-$23.37M	-$139.20M	-$13.06M	-$268.94M
Financing cash flow	-$67.61M	-$51.53M	-$101.50M	$2.03M	-$76.55M	-$2.44M	-$151.45M	$1.38M	-$74.80M	$333.69M	-$63.50M	$109.43M
Share repurchases	-	-	$100.00M	$0	-	-	$150.00M	$0	-	-	$0	$0
Stock-based compensation	$10.23M	$9.31M	$9.13M	$7.80M	$7.59M	$9.31M	$6.94M	$8.21M	$6.86M	$7.63M	$7.42M	$7.22M
Depreciation and amortization	$27.76M	$27.11M	$27.32M	$27.39M	$28.25M	$28.76M	$28.21M	$29.02M	$29.22M	$29.14M	$27.64M	$23.53M

Key ratios

Key ratios
Line item	Q2 2027 Sep 26, 2026	Q1 2027 Jun 27, 2026	Q4 2026* Mar 28, 2026	Q3 2026 Dec 27, 2025	Q2 2026 Sep 27, 2025	Q1 2026 Jun 28, 2025	Q4 2025* Mar 29, 2025	Q3 2025 Dec 28, 2024	Q2 2025 Sep 28, 2024	Q1 2025 Jun 29, 2024	Q4 2024* Mar 30, 2024	Q3 2024 Dec 30, 2023
Revenue growth, YoY	9.3%	5.6%	4.8%	-2.7%	-5.3%	-4.4%	-3.7%	3.7%	8.6%	8.0%	12.8%	10.1%
Net income growth, YoY	19.7%	-3.0%	-	19.3%	14.3%	-11.3%	184.7%	20.0%	35.8%	-6.5%	-30.7%	-5.2%
EPS growth, YoY	23.5%	2.9%	-	28.4%	22.7%	-5.4%	192.5%	21.3%	37.5%	-7.5%	-31.0%	-4.7%
Gross margin	61.7%	59.8%	57.2%	59.7%	59.5%	59.8%	58.4%	55.5%	54.2%	52.0%	51.2%	52.9%
Operating margin	21.0%	16.9%	-6.6%	19.9%	17.9%	16.8%	21.6%	16.9%	15.0%	11.8%	8.7%	13.7%
Net margin	12.9%	9.7%	-5.8%	13.2%	11.8%	10.6%	17.5%	10.8%	9.8%	11.4%	5.9%	9.3%
Free cash flow margin	31.7%	13.1%	15.4%	25.7%	32.5%	4.2%	30.5%	10.1%	11.4%	-9.8%	16.7%	-4.5%
Current ratio	2.84	3.08	2.95	1.75	1.64	1.72	1.62	3.97	3.49	3.76	2.56	2.92
Debt to equity	1.25	1.40	1.54	1.34	1.44	1.39	1.49	1.35	1.39	1.35	0.84	0.92

Source: XBRL data Haemonetics Corporation files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Feb 1, 2013.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

HAE peers

Company	Revenue	Growth	Net income	Net margin	Market cap
HAE	$1.38B	+4.1%	$103.91M	7.5%	$5.38B
SYKStryker Corporation	$26.30B	+7.9%	$3.62B	13.8%	$124.00B
MMM3M Company	$25.25B	+1.7%	$3.54B	14.0%	$97.47B
BSXBoston Scientific Corporation	$21.07B	+8.9%	$3.50B	16.6%	$63.81B
BDXBecton Dickinson and Company	$23.25B	+17.4%	$941.00M	4.0%	$58.63B
MDLNMedline Inc.	$30.68B	-	$683.00M	2.2%	$53.55B
RMDResMed Inc.	$5.73B	+9.0%	$1.59B	27.8%	$33.16B
DXCMDexCom Inc.	$5.10B	+13.0%	$991.00M	19.4%	$30.24B
WSTWest Pharmaceutical Services Inc.	$3.40B	+12.6%	$638.90M	18.8%	$28.78B

HAE FAQ

9 questions

What is HAE revenue?
Haemonetics Corporation (HAE) reported $1.38B of revenue for the twelve months ended Sep 26, 2026. That is up 4.1% from the year before. Revenue for fiscal 2026 was $1.33B.
Is HAE profitable?
Yes. Haemonetics Corporation earned $103.91M in net income for the twelve months ended Sep 26, 2026, a net margin of 7.5%.
How much cash and debt does HAE have?
Haemonetics Corporation reported $260.71M in cash and cash equivalents and $1.12B of debt on its most recent balance sheet in SEC filings.
How fast is HAE revenue growing?
Haemonetics Corporation's revenue changed -2.0% in fiscal 2026, to $1.33B. Its compound annual growth rate was +8.9% over 5 years.
What is HAE gross margin?
Haemonetics Corporation's gross profit was $824.31M on $1.38B of revenue for the twelve months ended Sep 26, 2026, a gross margin of 59.6%.
What is HAE free cash flow?
Haemonetics Corporation generated $298.24M of free cash flow for the twelve months ended Sep 26, 2026, which is operating cash flow of $344.93M less capital expenditures.
What is HAE earnings per share?
Diluted earnings per share were $2.26 for the twelve months ended Sep 26, 2026, from SEC filings, restated for any stock split those filings show.
When did HAE last report financial results?
The latest statements here come from Haemonetics Corporation's 10-Q filed on Nov 5, 2026, covering the period ended Sep 26, 2026.
Where does this HAE financial data come from?
Quantisnow builds these statements from the structured XBRL data Haemonetics Corporation files with the SEC. It is provided for information only and is not investment advice.